Bristol-Myers Squibb (BMY - Free Report) closed at $46.15 in the latest trading session, marking a -1.03% move from the prior day. This change lagged the S&P 500's 0.61% gain on the day. At the same time, the Dow added 0.71%, and the tech-heavy Nasdaq gained 0.53%.
Heading into today, shares of the biopharmaceutical company had lost 1.73% over the past month, lagging the Medical sector's loss of 1.29% and outpacing the S&P 500's loss of 3.77% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. The company is expected to report EPS of $1.03, up 1.98% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, up 4.82% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $4.18 per share and revenue of $24.11 billion. These results would represent year-over-year changes of +5.03% and +6.88%, respectively.
Investors might also notice recent changes to analyst estimates for BMY. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY currently has a Zacks Rank of #1 (Strong Buy).
Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 11.16. This valuation marks a discount compared to its industry's average Forward P/E of 14.36.
Meanwhile, BMY's PEG ratio is currently 2.18. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.09 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.